阿替普酶治疗急性缺血性卒中89例临床分析

被引：18

作者：

吴力娟

李致文

孔咏梅

李国锋

赵雪萌

魏玉清

机构：

[1] 河北省邢台市第三医院神经内科

来源：

河北医科大学学报 | 2017年 / 38卷 / 04期

关键词：

脑梗死; 组织型纤溶酶原激活物; 预后;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

1002 ;

摘要：

目的评价阿替普酶静脉溶栓的疗效及安全性,并分析影响患者预后的因素。方法回顾性分析进行重组组织型纤溶酶原激活剂静脉溶栓的89例急性脑梗死患者的临床资料,分析影响阿替普酶静脉溶栓疗效及安全性的因素。结果溶栓后当时神经功能良好者47例(52.81%),7d时神经功能恢复良好者56例(62.92%)。预后良好组年龄低于预后不良组,溶栓前美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分显著低于预后不良组,溶栓距发病时间短于预后不良组(P<0.05)。出血组溶栓前NIHSS评分高于未出血组,溶栓距发病时间长于未出血组,心房颤动发生率高于未出血组。结论应用阿替普酶静脉溶栓治疗急性脑梗死患者是安全有效的,且年龄越低、溶栓前NIHSS评分越低、溶栓距发病时间越短,3个月预后越好;另外,溶栓前NIHSS评分、溶栓距发病时间和心房颤动病史是影响溶栓后出血的几大危险因素,但颅内出血并不影响3个月预后。

引用

页码：386 / 389+394 +394

页数：5

共 11 条

[1] 急性脑梗死rt-PA溶栓治疗进展 [J].

刘静 ;

吴雅坤 ;

吕宪民 ;

曹亦宾 .

河北医科大学学报, 2016, 37 (03) :355-357

[2]

阿替普酶静脉溶栓治疗急性缺血性卒中临床研究[J]. 张佩兰,张辰昊,陈岩,李晨华,王育新.中国现代神经疾病杂志. 2013(04)

[3]

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials[J] . Jonathan Emberson,Kennedy R Lees,Patrick Lyden,Lisa Blackwell,Gregory Albers,Erich Bluhmki,Thomas Brott,Geoff Cohen,Stephen Davis,Geoffrey Donnan,James Grotta,George Howard,Markku Kaste,Masatoshi Koga,Ruediger von Kummer,Maarten Lansberg,Richard I Lindley,Gordon Murray,Jean Marc Olivot,Mark

[4]

NIHSS-time score easily predicts outcomes in rt-PA patients: The SAMURAI rt-PA registry[J] . Junya Aoki,Kazumi Kimura,Masatoshi Koga,Kazuomi Kario,Jyoji Nakagawara,Eisuke Furui,Yoshiaki Shiokawa,Yasuhiro Hasegawa,Satoshi Okuda,Hiroshi Yamagami,Yasushi Okada,Kensaku Shibazaki,Yuki Sakamoto,Kazunori Toyoda.Journal of the Neurological Sciences . 2013

[5]

Intravenous Thrombolysis and Endovascular Therapy for Acute Ischemic Stroke With Internal Carotid Artery Occlusion: A Systematic Review of Clinical Outcomes[J] . Maxim Mokin,Tareq Kass-Hout,Omar Kass-Hout,Travis M. Dumont,Peter Kan,Kenneth V. Snyder,L. Nelson Hopkins,Adnan H. Siddiqui,Elad I. Levy.Stroke . 2012 (9)

[6]

rt-PA for ischaemic stroke: what will the next question be?[J] . Didier Leys,Charlotte Cordonnier.The Lancet . 2012 (9834)

[7]

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J] . Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre

[8]

Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR[J] . Niaz Ahmed,Nils Wahlgren,Martin Grond,Michael Hennerici,Kennedy R Lees,Robert Mikulik,Mark Parsons,Risto O Roine,Danilo Toni,Peter Ringleb.Lancet Neurology . 2010 (9)

[9]

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J] . Kennedy R Lees,Erich Bluhmki,Rüdiger von Kummer,Thomas G Brott,Danilo Toni,James C Grotta,Gregory W Albers,Markku Kaste,John R Marler,Scott A Hamilton,Barbara C Tilley,Stephen M Davis,Geoffrey A Donnan,Werner Hacke.The Lancet . 2010 (9727)

[10]

Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic?[J] . Stroke: Journal of the American Heart Association . 2001 (6)

← 1 2 →